Last reviewed · How we verify
SARS-CoV-2 Virus 1x10^1 TCID50
At a glance
| Generic name | SARS-CoV-2 Virus 1x10^1 TCID50 |
|---|---|
| Sponsor | Imperial College London |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- COVID-19 Omicron BA.5 Subvariant Dose Finding Infection Study (PHASE1)
- SARS-CoV-2 Human Challenge Characterisation Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SARS-CoV-2 Virus 1x10^1 TCID50 CI brief — competitive landscape report
- SARS-CoV-2 Virus 1x10^1 TCID50 updates RSS · CI watch RSS
- Imperial College London portfolio CI